Additional file 5: Table S2. of Genome-wide identification and characterization of Glyceraldehyde-3-phosphate dehydrogenase genes family in wheat (Triticum aestivum)

Pairwise alignments of wheat Glyceraldehyde 3-phosphate dehydrogenase. (PDF 33 kb

Additional file 7: Figure S1. of Genome-wide identification and characterization of Glyceraldehyde-3-phosphate dehydrogenase genes family in wheat (Triticum aestivum)

Multiple alignment of wheat GAPDH amino acid sequences. (PDF 462 kb

Additional file 3: of Genome-wide identification and characterization of Glyceraldehyde-3-phosphate dehydrogenase genes family in wheat (Triticum aestivum)

The contigs and singletons of wheat GAPN that assembled from ESTs. (TXT 9 kb

Determination of specific oxygen uptake during climbing test until exhaustion in female sport climbers

Title of bachelor thesis Determination of climbing specific oxygen uptake during climbing test to vita maxima of sports climbers. Aims To assess the determination of climbing specific oxygen uptake during climbing test to vita maxima of sports climbers. Methods The study involved 14 women climbers. Their climbing ability moved about since 3th to 10th degree of UIAA. Maximal oxygen uptake was measured on climbing wall, where climbers climbed the vertival wall profile (90ř) at their own pace for 3 minutes. Specific test started on 105ř profile with increased climbing speed until individual exhaustion every 3 minutes. After that, the participant went a maximal running test on treadmill. Results Climbers achieved average of specific oxygen uptake was 38,8 ± 6,6 ml·kg-1 ·min-1 in maximal climbing test in gradient 105ř and 51,5 ± 2,1 ml·kg-1 ·min-1 in maximal running test on treadmill. The climbing performance most corelated with achievement of speed r = 0,91 and oxygen uptake r = 0,75. Result values present that minimal level of specific VO2 max 45 - 50 ml·kg-1 ·min-1 is very important for climbing difficult ways. Conclusion Climbing test is suitable for controlled training status of sport climbers. Key words Sport climbing, physiology, climbing test, oxygen uptak

Construction of two lanthanide complexes based on N- and O-donors: synthesis, luminescence, and biological activities

<p>Two new isostructural dinuclear complexes, Ln₂(4-cpa)₆(phen)₂ (Ln = Eu (<b>1</b>); Tb (<b>2</b>), 4-cpa^– = 4-chlorophenylacetate, phen = 1,10-phenanthroline), have been hydrothermally synthesized and characterized by IR spectroscopy, elemental analysis, thermogravimetric analysis, powder X-ray diffraction, and single-crystal X-ray diffraction. The lanthanides are bridged by two bidentate and two tridentate carboxylato groups to give centrosymmetric dimers with Ln···Ln separations of 3.967(2) and 3.937(3) Å for <b>1</b> and <b>2</b>, respectively. Each metal is nine-coordinate and exhibits a distorted tricapped trigonal prismatic geometry. Both <b>1</b> and <b>2</b> emit characteristic, intense luminescence at room temperature with lifetimes up to 0.890 ms (at 611 nm) and 0.995 ms (at 543 nm). Poor luminescence efficiency is observed for <b>2</b>. 4-Chlorophenylacetate, <b>1</b> and <b>2</b> have been screened for their phytogrowth-inhibitory activities against <i>Brassica napus</i> L. and <i>Echinochloa crusgalli</i> L., and the results are compared with the activity of quizalofop-P-ethyl.</p

The complete mitochondrial genome of <i>Batocera rubus</i> Linnaeus, 1785 (Coleoptera: Cerambycidae)

Batocera rubus severely impacts on the health of banyan trees. In this study, the whole mitochondrial genome for B. rubus was found to be 16,158 bp with a GC content of 23.9%, including 39.1% A, 37.0% T, 14.8% C, and 9.1% G. This genome contains 13 protein-coding genes, 22 tRNAs, and two rRNAs. Phylogenetic analysis revealed that B. rubus is close to Batocera celebiana. This study provides valuable information that can help improve the classification and phylogeny of B. rubus and facilitate further evolutionary studies.</p

Localized Surface Plasmon Resonance-Modulated Graphene-Based Optical Sensor for Ultrasensitive Immunoassays

Quantitative detection of disease markers at ultralow concentrations has rigorous requirements on the performance of graphene-based optical sensors (GOSs). In this work, a localized surface plasmon resonance-modulated GOS was developed by uniformly dispersing gold nanorods (AuNRs) on the graphene surface. As an optical sensor based on refractive index sensing, the refractive index resolution and sensitivity of the optical sensor reached 2.34 × 10–9 and 2.14 × 107 mV/RIU, respectively. The sensitivity of the optical sensor toward IgG immunoassay reached 6.5 mV (μg mL–1)−1, a value 7-fold that without the AuNRs. A limit of detection of 1.22 ng/mL toward IgG immunoassay was obtained, a value one-tenth that without the AuNRs. Most critically, it has been demonstrated that the improved performance of the optical sensor was attributed to the enhanced evanescent field on graphene caused by the coupling of the evanescent field and LSRR of AuNRs. The proposed optical sensor in this study has the characteristics of high sensitivity, being label-free, and a simple preparation process. The successful application of the proposed sensor will also greatly promote the development of quantitative detection of disease markers at ultralow concentrations

Image_1_Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis.jpeg

BackgroundRadiotherapy (RT)/Chemoradiotherapy (CRT) are important treatments for all stages of esophageal cancer (EC). The combination of immune checkpoint inhibitors (ICIs) with RT/CRT seems to be promising avenue for the treatment of EC. Therefore, a systematic review and meta-analysis was performed in order to assess the safety and efficacy of RT/CRT and ICI combination therapy for EC patients.MethodsPubMed and several other databases were searched (according to specific criteria) to find relevant studies published prior to the 31st of December 2021.Results1962 articles were identified for screening, and six trials containing 668 patients were identified and pooled to determine the one- and two-year overall survival (OS), which were 84.5% (95% confidence interval (CI): 69.9%-100%) and 68.3% (95% CI: 49.0%-95.1%), respectively. Additionally, the rate of pooled grade 3-5 adverse reactions was 41.0% (95% CI: 31.2%-51.2%). The rate of specific grade 3-5 adverse reactions are as follows: lymphopenia (36.8%-60%), esophagitis (20%), anastomotic leakage (18%), esophageal fistula (10%), pain (10%), leukopenia (5.3%-10%), esophageal hemorrhage (2.5%-5%), chyle leakage (3%), fatigue (5%), cough (2.7%-5%), diarrhea (2.7%), pulmonary embolism (2.5%) and allergic reaction (2.5%). The pooled rate of pneumonitis of grade 3-5 and grade 1-5 was 0.8% (95% CI: 0.1%-0.16%, I2: 0%) and 5.4% (95% CI: 2.0%-14.2%, I2: 82%). For thoracic complication, esophagitis was 63.6% (95% CI: 42.4%-80.6%), which appeared to be more frequent with the combination of ICIs to RT/CRT (12%-37.7%). Other thoracic complications include esophageal hemorrhage (2.5%-10%), esophageal fistula (6%-10%) and anastomotic leakage (6%-21%). Additionally, some of the trials did not report cardiac related adverse reactions. The subgroup analyses also revealed that the pooled rate patients with grade 3-5 pneumonitis was higher for CRT/RT with concurrent and sequential ICI treatment (1.9%) than other groups (0.8%).ConclusionThis study suggests that the addition of ICIs to RT/CRT for EC patients may be both safe and feasible. However, larger randomized studies are needed to confirm these results.</p

Table_1_Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis.docx

BackgroundRadiotherapy (RT)/Chemoradiotherapy (CRT) are important treatments for all stages of esophageal cancer (EC). The combination of immune checkpoint inhibitors (ICIs) with RT/CRT seems to be promising avenue for the treatment of EC. Therefore, a systematic review and meta-analysis was performed in order to assess the safety and efficacy of RT/CRT and ICI combination therapy for EC patients.MethodsPubMed and several other databases were searched (according to specific criteria) to find relevant studies published prior to the 31st of December 2021.Results1962 articles were identified for screening, and six trials containing 668 patients were identified and pooled to determine the one- and two-year overall survival (OS), which were 84.5% (95% confidence interval (CI): 69.9%-100%) and 68.3% (95% CI: 49.0%-95.1%), respectively. Additionally, the rate of pooled grade 3-5 adverse reactions was 41.0% (95% CI: 31.2%-51.2%). The rate of specific grade 3-5 adverse reactions are as follows: lymphopenia (36.8%-60%), esophagitis (20%), anastomotic leakage (18%), esophageal fistula (10%), pain (10%), leukopenia (5.3%-10%), esophageal hemorrhage (2.5%-5%), chyle leakage (3%), fatigue (5%), cough (2.7%-5%), diarrhea (2.7%), pulmonary embolism (2.5%) and allergic reaction (2.5%). The pooled rate of pneumonitis of grade 3-5 and grade 1-5 was 0.8% (95% CI: 0.1%-0.16%, I2: 0%) and 5.4% (95% CI: 2.0%-14.2%, I2: 82%). For thoracic complication, esophagitis was 63.6% (95% CI: 42.4%-80.6%), which appeared to be more frequent with the combination of ICIs to RT/CRT (12%-37.7%). Other thoracic complications include esophageal hemorrhage (2.5%-10%), esophageal fistula (6%-10%) and anastomotic leakage (6%-21%). Additionally, some of the trials did not report cardiac related adverse reactions. The subgroup analyses also revealed that the pooled rate patients with grade 3-5 pneumonitis was higher for CRT/RT with concurrent and sequential ICI treatment (1.9%) than other groups (0.8%).ConclusionThis study suggests that the addition of ICIs to RT/CRT for EC patients may be both safe and feasible. However, larger randomized studies are needed to confirm these results.</p

Image_4_Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis.jpeg

BackgroundRadiotherapy (RT)/Chemoradiotherapy (CRT) are important treatments for all stages of esophageal cancer (EC). The combination of immune checkpoint inhibitors (ICIs) with RT/CRT seems to be promising avenue for the treatment of EC. Therefore, a systematic review and meta-analysis was performed in order to assess the safety and efficacy of RT/CRT and ICI combination therapy for EC patients.MethodsPubMed and several other databases were searched (according to specific criteria) to find relevant studies published prior to the 31st of December 2021.Results1962 articles were identified for screening, and six trials containing 668 patients were identified and pooled to determine the one- and two-year overall survival (OS), which were 84.5% (95% confidence interval (CI): 69.9%-100%) and 68.3% (95% CI: 49.0%-95.1%), respectively. Additionally, the rate of pooled grade 3-5 adverse reactions was 41.0% (95% CI: 31.2%-51.2%). The rate of specific grade 3-5 adverse reactions are as follows: lymphopenia (36.8%-60%), esophagitis (20%), anastomotic leakage (18%), esophageal fistula (10%), pain (10%), leukopenia (5.3%-10%), esophageal hemorrhage (2.5%-5%), chyle leakage (3%), fatigue (5%), cough (2.7%-5%), diarrhea (2.7%), pulmonary embolism (2.5%) and allergic reaction (2.5%). The pooled rate of pneumonitis of grade 3-5 and grade 1-5 was 0.8% (95% CI: 0.1%-0.16%, I2: 0%) and 5.4% (95% CI: 2.0%-14.2%, I2: 82%). For thoracic complication, esophagitis was 63.6% (95% CI: 42.4%-80.6%), which appeared to be more frequent with the combination of ICIs to RT/CRT (12%-37.7%). Other thoracic complications include esophageal hemorrhage (2.5%-10%), esophageal fistula (6%-10%) and anastomotic leakage (6%-21%). Additionally, some of the trials did not report cardiac related adverse reactions. The subgroup analyses also revealed that the pooled rate patients with grade 3-5 pneumonitis was higher for CRT/RT with concurrent and sequential ICI treatment (1.9%) than other groups (0.8%).ConclusionThis study suggests that the addition of ICIs to RT/CRT for EC patients may be both safe and feasible. However, larger randomized studies are needed to confirm these results.</p